Provided by Tiger Trade Technology Pte. Ltd.

Biogen

216.65
-1.8500-0.85%
Post-market: 219.002.35+1.08%17:06 EDT
Volume:830.99K
Turnover:180.42M
Market Cap:31.99B
PE:38.48
High:218.89
Open:216.47
Low:213.58
Close:218.50
52wk High:222.85
52wk Low:133.53
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.48
T/O Rate:0.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.70
PE(LYR):24.65

Loading ...

Canaccord Genuity Remains a Buy on Biogen (BIIB)

TIPRANKS
·
Jul 14

IQLIK Approval Seen as Commercial Enhancer, Not Fundamental Shift, as Biogen Neutral Rating and $200 Price Target Remain Unchanged

TIPRANKS
·
Jul 14

Is Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector?

Simply Wall St.
·
Jul 14

Eisai Inc: Leqembi Iqlik Initiation Dosing Expected to be Available in U.S. Late August 2026

THOMSON REUTERS
·
Jul 14

FDA Approves Leqembi Iqlik® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

THOMSON REUTERS
·
Jul 14

Biogen Inc. Stock Rallies 5.0%, Outperforms Peers

Dow Jones
·
Jul 14

Movement Alert|Biogen Rises 5.26% in Regular Trading, FDA Approves Leqembi Subcutaneous Injection New Initiation Regimen

Market Focus
·
Jul 14

Early subQ approval should help Biogen regain market share, says RBC

TIPRANKS
·
Jul 14

Biogen Rises After FDA Clears At-home Use of Alzheimer's Drug

Reuters
·
Jul 14

Shares of Biogen up 5% After US FDA Approves Subcutaneous Starting Dose for Alzheimer's Drug Leqembi

THOMSON REUTERS
·
Jul 14

FDA: Approves New Starting Dosage Regimen for Leqembi Subcutaneous Formulation for Alzheimer’s Disease Treatment

THOMSON REUTERS
·
Jul 14

Dow Jones Top Company Headlines at 11 am ET: Meta Lifts Cost of Louisiana Data Center to $50 Billion | Intel ...

Dow Jones
·
Jul 13

BMO Capital Sticks to Its Hold Rating for Biogen (BIIB)

TIPRANKS
·
Jul 13

Biogen Stock is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details

Dow Jones
·
Jul 13

Wedbush Raises Price Target on Biogen to $201 From $196, Keeps Neutral Rating

MT Newswires Live
·
Jul 13

Biogen : Truist Securities Raises to Buy from Hold; Raises Target Price to $235 from $190

THOMSON REUTERS
·
Jul 13

This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Benzinga
·
Jul 13

Biogen Raised to Buy from Hold by Truist Securities

Dow Jones
·
Jul 13

Biogen upgraded to Buy from Hold at Truist

TIPRANKS
·
Jul 13

Biogen, Eisai Report Subcutaneous Leqembi Matches IV Formulation in Early Alzheimer's Study

MT Newswires Live
·
Jul 13